psychedelic – Benefits Canada.com https://www.benefitscanada.com Canada's most influential pension and benefits publication for decision-makers Fri, 03 May 2024 21:03:19 +0000 en-US hourly 1 https://wordpress.org/?v=4.9.8 Survey finds 40% of workers taking time off due to mental-health concerns https://www.benefitscanada.com/benefits/health-wellness/40-of-workers-taking-time-off-due-to-mental-health-concerns-survey/ Mon, 08 May 2023 13:00:54 +0000 https://www.benefitscanada.com/?p=137424 Two-fifths (40 per cent) of Canadian employees say they’ve taken time off work in the last five years due to mental-health concerns, according to a new survey by wellness benefits provider Heal-3 and the Future Skills Centre. The survey, which polled more than 500 workers, found among respondents who took time off for mental-health reasons, […]

The post Survey finds 40% of workers taking time off due to mental-health concerns appeared first on Benefits Canada.com.

]]> Head to head: Should psychedelics be used in the treatment of mental-health conditions? https://www.benefitscanada.com/archives_/benefits-canada-archive/head-to-head-should-psychedelics-be-used-in-the-treatment-of-mental-health-conditions/ Fri, 11 Feb 2022 13:59:43 +0000 https://www.benefitscanada.com/?p=115818 Hallucinogens like ecstasy and magic mushrooms are being used in the treatment of depression and post-traumatic stress disorder, but the risks may outweigh the benefits. Erika Dyck, Canada research chair and professor in history of health and social justice at the University of Saskatchewan Psychedelics may conjure images of beatniks, hippies and Deadheads, but recent […]

The post Head to head: Should psychedelics be used in the treatment of mental-health conditions? appeared first on Benefits Canada.com.

]]> Is there a place for psychedelics in institutional portfolios? https://www.benefitscanada.com/news/cir-news-news/is-there-a-place-for-psychedelics-in-institutional-portfolios/ Thu, 20 May 2021 13:00:02 +0000 https://www.benefitscanada.com/?p=100769 With the global psychedelic drugs market projected to grow at a compound annual growth rate of 12.36 per cent between 2021 and 2027 to a value of US$10.75 billion in 2027 and the world’s first psychedelic exchange-traded fund launched in Canada at the start of the year, should institutional investors be taking notice? Read: Is it […]

The post Is there a place for psychedelics in institutional portfolios? appeared first on Benefits Canada.com.

]]>